| The Impact of Suboptimal 25‐hydroxyvitamin D Levels and Cholecalciferol Replacement on the Pharmacokinetics of Oral Midazolam in Control Subjects and Patients with Chronic Kidney Disease | Journal of Clinical Pharmacology | |
| Effects of body weight, smoking status and sex on plasma concentrations of once-monthly paliperidone palmitate. | Expert Review of Clinical Pharmacology | 2021 |
| Pharmacogenetics: A precision medicine approach to combatting the opioid epidemic | JACCP Journal of the American College of Clinical Pharmacy | 2022 |
| Strategies for Incorporating Pharmacokinetic Studies into Oncology Phase I Trials | | 2020 |
| Early Phase Metabolic Research with Reference to Special Populations | | 2019 |
| [Common sense of diosmin administration in combined treatment of hemorrhoids] | Khirurgiya | 2018 |
| Probe Cocktail Studies | | 2018 |
| Transporteiwitten en metabole enzymen betrokken bij farmacokinetische interacties tussen geneesmiddelen | | 2018 |
| Transporteiwitten en metabole enzymen betrokken bij farmacokinetische interacties tussen geneesmiddelen | | 2017 |
| Transporteiwitten en metabole enzymen betrokken bij farmacokinetische interacties tussen geneesmiddelen | | 2015 |
| Renal Organic Cation and Anion Transport: From Physiology to Genes☆ | | 2014 |
| Possible Drug Interaction between Oxycodone and Erythromycin: A Case Report and Analyses of Spontaneous Reporting Systems of Adverse Drug Reactions | Japanese Journal of Clinical Pharmacology and Therapeutics | 2018 |
| Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial | PLoS ONE | 2017 |
| Unmasking efavirenz neurotoxicity: Time matters to the underlying mechanisms | European Journal of Pharmaceutical Sciences | 2017 |
| Management of Medication-Related Adverse Effects | | 2014 |
| Alzheimer's and Parkinson's Disease Novel Therapeutic Target | | 2021 |
| Pharmacokinetic Correlates of Once-Monthly Paliperidone Palmitate-Related Adverse Drug Reactions | Clinical Pharmacokinetics | 2021 |
| S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adults | European Journal of Clinical Pharmacology | 2021 |
| Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs | European Journal of Clinical Pharmacology | 2021 |
| Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban-Renal and Hepatic Impairment and Drug-Drug Interaction Potential | Journal of Clinical Pharmacology | 2021 |
| Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV | Clinical Pharmacokinetics | 2020 |
| Direct oral anticoagulants in patients with hematologic malignancies | Hematological Oncology | 2020 |
| Prevalence and sort of pharmacokinetic drug-drug interactions in hospitalized psychiatric patients | Journal of Neural Transmission | 2020 |
| Risk of severe hypoglycemic events from amiodarone-sulfonylureas interactions: A population-based nested case-control study | Pharmacoepidemiology and Drug Safety | 2020 |
| Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions | Pharmaceutical Research | 2020 |
| Pharmacogenomics | | 2020 |
| Evaluation of the effect of P-glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours | British Journal of Clinical Pharmacology | 2020 |
| Ketamine in seizure management and future pharmacogenomic considerations | Pharmacogenomics Journal | 2020 |
| A Scoping Review of the Evidence Behind Cytochrome P450 2D6 Isoenzyme Inhibitor Classifications | Clinical Pharmacology and Therapeutics | 2020 |
| Investigating the clinical factors and comedications associated with circulating levels of atorvastatin and its major metabolites in secondary prevention | British Journal of Clinical Pharmacology | 2020 |
| Correlation of the biotransformation of H3B-6527 in dog and human hepatocytes with the metabolic profile of C-H3B-6527 in a dog mass balance study | Xenobiotica | 2020 |
| Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI | Clinical Pharmacology and Therapeutics | 2020 |
| Effects of shuanghuanglian injection on the activities of CYP1A2, 2C11, 2D1 and 3A1/2 in rats in vivo and in vitro | Xenobiotica | 2019 |
| Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA) | Cancer Chemotherapy and Pharmacology | 2019 |
| Management strategies of the interaction between direct oral anticoagulant and drug-metabolizing enzyme inducers | Journal of Thrombosis and Thrombolysis | 2019 |
| Comparison of the hepatic metabolism of triazolam in wild-type andCyp3a-knockout mice for understanding CYP3A-mediated metabolism inCYP3A-humanised mice | Xenobiotica | 2019 |
| Safe and Appropriate Use of Methadone in Hospice and Palliative Care: Expert Consensus White Paper | Journal of Pain and Symptom Management | 2019 |
| An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes | Journal of Neural Transmission | 2019 |
| Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam | CPT: Pharmacometrics and Systems Pharmacology | 2019 |
| Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor | Journal of Medicinal Chemistry | 2019 |
| Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects | Clinical Drug Investigation | 2019 |
| Drug-Drug Interactions of Infectious Disease Treatments in Low-Income Countries: A Neglected Topic? | Clinical Pharmacology and Therapeutics | 2019 |
| Assessment of preclinical drug interactions of bedaquiline by a highly sensitive LC-ESI-MS/MS based bioanalytical method | Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences | 2019 |
| Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial | Journal of Thrombosis and Thrombolysis | 2019 |
| Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene-drug pairs across ambulatory care settings | Genetics in Medicine | 2019 |
| Pharmacokinetic correlates of venlafaxine: associated adverse reactions | European Archives of Psychiatry and Clinical Neuroscience | 2019 |
| Non randomized study on the potential of nitisinone to inhibit cytochrome P450 2C9, 2D6, 2E1 and the organic anion transporters OAT1 and OAT3 in healthy volunteers | European Journal of Clinical Pharmacology | 2019 |
| Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy | Journal of Thrombosis and Thrombolysis | 2019 |
| Efficacy of Tramadol for Pain Management in Patients Receiving Strong Cytochrome P450 2D6 Inhibitors | Pharmacotherapy | 2019 |
| Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults | Journal of Clinical Pharmacology | 2019 |
